Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Apatinib in Advanced Mucosal Melanoma
NCT03986515Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2019
- Primary completion
- May 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in mucosal melanoma (MM), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate at 3 months. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT03986515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03986515.